Galectin-3 up-regulation in hypoxic and nutrient deprived microenvironments promotes cell survival

PLoS ONE

Volumn 9, Issue 11, 2014, Pages

  Ikemori, Rafael Yamashita ^a   Machado, Camila Maria Longo ^a,b   Furuzawa, Karina Mie ^a   Nonogaki, Suely ^c   Osinaga, Eduardo ^d   Umezawa, Kazuo ^e   De Carvalho, Marcelo Alex ^f   Verinaud, Liana ^g   Chammas, Roger ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Laborató Rio de Investigação Médica Em Medicina Nuclear LIM43   (Brazil)

^c INSTITUTO ADOLFO LUTZ   (Brazil)

^d UNIVERSIDAD DE LA REPÚBLICA   (Uruguay)

^e AICHI MEDICAL UNIVERSITY   (Japan)

^f Instituto Federal Do Rio de Janeiro   (Brazil)

^g UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 7; COBALT CHLORIDE; GALECTIN 3; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; REACTIVE OXYGEN METABOLITE; SMALL INTERFERING RNA; OXYGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DEATH; CELL PROTECTION; CELL SURVIVAL; CELLULAR DISTRIBUTION; CONTROLLED STUDY; GENE EXPRESSION REGULATION; GENE SILENCING; GLIOMA CELL LINE; HUMAN; HUMAN CELL; HYPOXIA; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NG97HT CELL LINE; NONHUMAN; PROTEIN AGGREGATION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN SYNTHESIS; STARVATION; TUMOR ENGRAFTMENT; TUMOR GROWTH; TUMOR MICROENVIRONMENT; UPREGULATION; ANIMAL; ANOXIA; CELL HYPOXIA; GENETICS; GLIOBLASTOMA; METABOLISM; NUDE MOUSE; PATHOLOGY; RNA INTERFERENCE; TUMOR CELL LINE;

ANIMALS; ANOXIA; CELL HYPOXIA; CELL LINE, TUMOR; CELL SURVIVAL; GALECTIN 3; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MICE, NUDE; NF-KAPPA B; OXYGEN; RNA INTERFERENCE; RNA, SMALL INTERFERING; UP-REGULATION;

EID: 84932159480     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0111592     Document Type: Article

References (82)

1. Dumic J, Dabelic S, Flogel M (2006) Galectin-3: An open-ended story. Biochim Biophys Acta 1760: 616-635.
2. Debray C, Vereecken P, Belot N, Teillard P, Brion JP, et al. (2004) Multifaceted role of galectin-3 on human glioblastoma cell motility. Biochem Biophys Res Commun 325: 1393-1398.
3. Nangia-Makker P, Honjo Y, Sarvis R, Akahani S, Hogan V, et al. (2000) Galectin-3 induces endothelial cell morphogenesis and angiogenesis. Am J - Pathol 156: 899-909.
4. Yoshii T, Fukumori T, Honjo Y, Inohara H, Kim HR, et al. (2002) Galectin-3 phosphorylation is required for its anti-apoptotic function and cell cycle arrest. J Biol Chem 277: 6852-6857.
5. Markowska AI, Jefferies KC, Panjwani N (2011) Galectin-3 protein modulates cell surface expression and activation of vascular endothelial growth factor receptor 2 in human endothelial cells. J Biol Chem 286: 29913-29921.
6. Piccolo E, Tinari N, Semeraro D, Traini S, Fichera I, et al. (2013) LGALS3BP, lectin galactoside-binding soluble 3 binding protein, induces vascular endothelial growth factor in human breast cancer cells and promotes angiogenesis. J Mol Med (Berl) 91: 83-94.
7. Moon BK, Lee YJ, Battle P, Jessup JM, Raz A, et al. (2001) Galectin-3 protects human breast carcinoma cells against nitric oxide-induced apoptosis: Implication of galectin-3 function during metastasis. Am J Pathol 159: 1055-1060.
8. Song YK, Billiar TR, Lee YJ (2002) Role of galectin-3 in breast cancer metastasis: Involvement of nitric oxide. Am J Pathol 160: 1069-1075.
9. Dagher SF, Wang JL, Patterson RJ (1995) Identification of galectin-3 as a factor in pre-mRNA splicing. Proc Natl Acad Sci U S A 92: 1213-1217.
10. Lin HM, Pestell RG, Raz A, Kim HR (2002) Galectin-3 enhances cyclin D(1) promoter activity through SP1 and a cAMP-responsive element in human breast epithelial cells. Oncogene 21: 8001-8010.
11. Paron I, Scaloni A, Pines A, Bachi A, Liu FT, et al. (2003) Nuclear localization of Galectin-3 in transformed thyroid cells: A role in transcriptional regulation. Biochem Biophys Res Commun 302: 545-553.
12. Akahani S, Nangia-Makker P, Inohara H, Kim HR, Raz A (1997) Galectin-3: A novel antiapoptotic molecule with a functional BH1 (NWGR) domain of Bcl-2 family. Cancer Res 57: 5272-5276.
13. Yang RY, Hsu DK, Liu FT (1996) Expression of galectin-3 modulates T-cell growth and apoptosis. Proc Natl Acad Sci U S A 93: 6737-6742.
14. Califice S, Castronovo V, Bracke M, van den Brule F (2004) Dual activities of galectin-3 in human prostate cancer: Tumor suppression of nuclear galectin-3 vs tumor promotion of cytoplasmic galectin-3. Oncogene 23: 7527-7536.
15. Villa-Verde DM, Silva-Monteiro E, Jasiulionis MG, Farias-De-Oliveira DA, Brentani RR, et al. (2002) Galectin-3 modulates carbohydrate-dependent thymocyte interactions with the thymic microenvironment. Eur J Immunol 32: 1434-1444.
16. Camby I, Belot N, Rorive S, Lefranc F, Maurage CA, et al. (2001) Galectins are differentially expressed in supratentorial pilocytic astrocytomas, astrocytomas, anaplastic astrocytomas and glioblastomas, and significantly modulate tumor astrocyte migration. Brain Pathol 11: 12-26.
17. Kuklinski S, Pesheva P, Heimann C, Urschel S, Gloor S, et al. (2000) Expression pattern of galectin-3 in neural tumor cell lines. J Neurosci Res 60: 45-57.
18. Zhuo Y, Chammas R, Bellis SL (2008) Sialylation of beta1 integrins blocks cell adhesion to galectin-3 and protects cells against galectin-3-induced apoptosis. J Biol Chem 283: 22177-22185.
19. Mazurek N, Sun YJ, Price JE, Ramdas L, Schober W, et al. (2005) Phosphorylation of galectin-3 contributes to malignant transformation of human epithelial cells via modulation of unique sets of genes. Cancer Res 65: 10767- 10775.
20. Olbryt M, Jarzab M, Jazowiecka-Rakus J, Simek K, Szala S, et al. (2006) Gene expression profile of B 16(F10) murine melanoma cells exposed to hypoxic conditions in vitro. Gene Expr 13: 191-203.
21. Greijer AE, van der Groep P, Kemming D, Shvarts A, Semenza GL, et al. (2005) Up-regulation of gene expression by hypoxia is mediated predominantly by hypoxia-inducible factor 1 (HIF-1). J Pathol 206: 291-304.
22. Hu R, Jin H, Zhou S, Yang P, Li X (2007) Proteomic analysis of hypoxiainduced responses in the syncytialization of human placental cell line BeWo. Placenta 28: 399-407.
23. Brat DJ, Van Meir EG (2004) Vaso-occlusive and prothrombotic mechanisms associated with tumor hypoxia, necrosis, and accelerated growth in glioblastoma. Lab Invest 84: 397-405.
24. Brat DJ, Castellano-Sanchez AA, Hunter SB, Pecot M, Cohen C, et al. (2004) Pseudopalisades in glioblastoma are hypoxic, express extracellular matrix proteases, and are formed by an actively migrating cell population. Cancer Res 64: 920-927.
25. Rong Y, Durden DL, Van Meir EG, Brat DJ (2006) 'Pseudopalisading' necrosis in glioblastoma: A familiar morphologic feature that links vascular pathology, hypoxia, and angiogenesis. J Neuropathol Exp Neurol 65: 529-539.
26. Sondergaard KL, Hilton DA, Penney M, Ollerenshaw M, Demaine AG (2002) Expression of hypoxia-inducible factor 1alpha in tumours of patients with glioblastoma. Neuropathol Appl Neurobiol 28: 210-217.
27. Neder L, Marie SK, Carlotti CG Jr, Gabbai AA, Rosemberg S, et al. (2004) Galectin-3 as an immunohistochemical tool to distinguish pilocytic astrocytomas from diffuse astrocytomas, and glioblastomas from anaplastic oligodendrogliomas. Brain Pathol 14: 399-405.
28. Bresalier RS, Yan PS, Byrd JC, Lotan R, Raz A (1997) Expression of the endogenous galactose-binding protein galectin-3 correlates with the malignant potential of tumors in the central nervous system. Cancer 80: 776-787.
29. Gordower L, Decaestecker C, Kacem Y, Lemmers A, Gusman J, et al. (1999) Galectin-3 and galectin-3-binding site expression in human adult astrocytic tumours and related angiogenesis. Neuropathol Appl Neurobiol 25: 319-330.
30. Le Mercier M, Fortin S, Mathieu V, Kiss R, Lefranc F (2010) Galectins and gliomas. Brain Pathol 20: 17-27.
31. Strik HM, Deininger MH, Frank B, Schluesener HJ, Meyermann R (2001) Galectin-3: cellular distribution and correlation with WHO-grade in human gliomas. J Neurooncol 53: 13-20.
32. D'Haene N, Maris C, Rorive S, Decaestecker C, Le Mercier M, et al. (2014) Galectins and neovascularization in central nervous system tumors. Glycobiology 24: 892-898.
33. Grippo MC, Penteado PF, Carelli EF, Cruz-Hofling MA, Verinaud L (2001) Establishment and partial characterization of a continuous human malignant glioma cell line: NG97. Cell Mol Neurobiol 21: 421-428.
34. Machado CM, Ikemori RY, Zorzeto TQ, Nogueira AC, Barbosa SD, et al. (2008) Characterization of cells recovered from the xenotransplanted NG97 human-derived glioma cell line subcultured in a long-term in vitro. BMC Cancer 8: 291.
35. Kanaya K, Kamitani T (2003) pVHL-independent ubiquitination of HIF1alpha and its stabilization by cobalt ion. Biochem Biophys Res Commun 306: 750- 755.
36. Yuan Y, Hilliard G, Ferguson T, Millhorn DE (2003) Cobalt inhibits the interaction between hypoxia-inducible factor-alpha and von Hippel-Lindau protein by direct binding to hypoxia-inducible factor-alpha. J Biol Chem 278: 15911-15916.
37. Pfaffl MW (2001) A new mathematical model for relative quantification in realtime RT-PCR. Nucleic Acids Res 29: E45.
38. Umezawa K, Chaicharoenpong C (2002) Molecular design and biological activities of NF-kappaB inhibitors. Mol Cells 14: 163-167.
39. Ausubel FM (1995) Short protocols in molecular biology: A compendium of methods from Current protocols in molecular biology. New York; Chichester: Wiley.
40. Roskams J, Rodgers L, Mellick AS (2002) Lab ref: A handbook of recipes, reagents, and other reference tools for use at the bench. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press.
41. Denko NC (2008) Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat Rev Cancer 8: 705-713.
42. Iyer NV, Kotch LE, Agani F, Leung SW, Laughner E, et al. (1998) Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1 alpha. Genes Dev 12: 149-162.
43. Stiehl DP, Wirthner R, Koditz J, Spielmann P, Camenisch G, et al. (2006) Increased prolyl 4-hydroxylase domain proteins compensate for decreased oxygen levels. Evidence for an autoregulatory oxygen-sensing system. J Biol Chem 281: 23482-23491.
44. Zeng Y, Danielson KG, Albert TJ, Shapiro IM, Risbud MV (2007) HIF-1 alpha is a regulator of galectin-3 expression in the intervertebral disc. J Bone Miner Res 22: 1851-1861.
45. Kadrofske MM, Openo KP, Wang JL (1998) The human LGALS3 (galectin-3) gene: Determination of the gene structure and functional characterization of the promoter. Arch Biochem Biophys 349: 7-20.
46. de Haro C, Mendez R, Santoyo J (1996) The eIF-2alpha kinases and the control of protein synthesis. FASEB J 10: 1378-1387.
47. Lakshminarayan R, Wunder C, Becken U, Howes MT, Benzing C, et al. (2014) Galectin-3 drives glycosphingolipid-dependent biogenesis of clathrin-independent carriers. Nat Cell Biol 16: 595-606.
48. Huflejt ME, Turck CW, Lindstedt R, Barondes SH, Leffler H (1993) L-29, a soluble lactose-binding lectin, is phosphorylated on serine 6 and serine 12 in vivo and by casein kinase I. J Biol Chem 268: 26712-26718.
49. Mazurek N, Conklin J, Byrd JC, Raz A, Bresalier RS (2000) Phosphorylation of the beta-galactoside-binding protein galectin-3 modulates binding to its ligands. J Biol Chem 275: 36311-36315.
50. Yamazaki K, Kawai A, Kawaguchi M, Hibino Y, Li F, et al. (2001) Simultaneous induction of galectin-3 phosphorylated on tyrosine residue, p21(WAF1/Cip1/Sdi1), and the proliferating cell nuclear antigen at a distinctive period of repair of hepatocytes injured by CCl4. Biochem Biophys Res Commun 280: 1077-1084.
51. Takenaka Y, Fukumori T, Yoshii T, Oka N, Inohara H, et al. (2004) Nuclear export of phosphorylated galectin-3 regulates its antiapoptotic activity in response to chemotherapeutic drugs. Mol Cell Biol 24: 4395-4406.
52. Hill M, Mazal D, Biron VA, Pereira L, Ubillos L, et al. (2010) A novel clinically relevant animal model for studying galectin-3 and its ligands during colon carcinogenesis. J Histochem Cytochem 58: 553-565.
53. Chen HJ, Zheng ZC, Yuan BQ, Liu Z, Jing J, et al. (2012) The effect of galectin- 3 genetic variants on the susceptibility and prognosis of gliomas in a Chinese population. Neurosci Lett 518: 1-4.
54. Li X, Ma Q, Wang J, Liu X, Yang Y, et al. (2010) c-Abl and Arg tyrosine kinases regulate lysosomal degradation of the oncoprotein Galectin-3. Cell Death Differ 17: 1277-1287.
55. Nam SY, Ko YS, Jung J, Yoon J, Kim YH, et al. (2011) A hypoxia-dependent upregulation of hypoxia-inducible factor-1 by nuclear factor-kappaB promotes gastric tumour growth and angiogenesis. Br J Cancer 104: 166-174.
56. van Uden P, Kenneth NS, Rocha S (2008) Regulation of hypoxia-inducible factor-1alpha by NF-kappaB. Biochem J 412: 477-484.
57. Culver C, Sundqvist A, Mudie S, Melvin A, Xirodimas D, et al. (2010) Mechanism of hypoxia-induced NF-kappaB. Mol Cell Biol 30: 4901-4921.
58. Melvin A, Mudie S, Rocha S (2011) Further insights into the mechanism of hypoxia-induced NFkappaB. [corrected]. Cell Cycle 10: 879-882.
59. Hirao M, Tamai N, Tsumaki N, Yoshikawa H, Myoui A (2006) Oxygen tension regulates chondrocyte differentiation and function during endochondral ossification. J Biol Chem 281: 31079-31092.
60. Stock M, Schafer H, Stricker S, Gross G, Mundlos S, et al. (2003) Expression of galectin-3 in skeletal tissues is controlled by Runx2. J Biol Chem 278: 17360- 17367.
61. Vladimirova V, Waha A, Luckerath K, Pesheva P, Probstmeier R (2008) Runx2 is expressed in human glioma cells and mediates the expression of galectin-3. J Neurosci Res 86: 2450-2461.
62. Zhang HY, Jin L, Stilling GA, Ruebel KH, Coonse K, et al. (2009) RUNX1 and RUNX2 upregulate Galectin-3 expression in human pituitary tumors. Endocrine 35: 101-111.
63. Wagner M, Klein CL, Kleinert H, Euchenhofer C, Forstermann U, et al. (1997) Heavy metal ion induction of adhesion molecules and cytokines in human endothelial cells: The role of NF-kappaB, I kappaB-alpha and AP-1. Pathobiology.65: 241-252.
64. Araya R, Uehara T, Nomura Y (1998) Hypoxia induces apoptosis in human neuroblastoma SK-N-MC cells by caspase activation accompanying cytochrome c release from mitochondria. FEBS Lett 439: 168-172.
65. Zeno S, Zaaroor M, Leschiner S, Veenman L, Gavish M (2009) CoCl(2) induces apoptosis via the 18 kDa translocator protein in U118MG human glioblastoma cells. Biochemistry 48: 4652-4661.
66. Reed JC (1997) Cytochrome c: can9t live with it-can't live without it. Cell 91: 559-562.
67. Steinbach JP, Wolburg H, Klumpp A, Probst H, Weller M (2003) Hypoxiainduced cell death in human malignant glioma cells: Energy deprivation promotes decoupling of mitochondrial cytochrome c release from caspase processing and necrotic cell death. Cell Death Differ 10: 823-832.
68. Rovetta F, Stacchiotti A, Faggi F, Catalani S, Apostoli P, et al. (2013) Cobalt triggers necrotic cell death and atrophy in skeletal C2C12 myotubes. Toxicol Appl Pharmacol 271: 196-205.
69. Celegato M, Borghese C, Umezawa K, Casagrande N, Colombatti A, et al. (2014) The NF-kappaB inhibitor DHMEQ decreases survival factors, overcomes the protective activity of microenvironment and synergizes with chemotherapy agents in classical Hodgkin lymphoma. Cancer Lett 349: 26-34.
70. Silva-Monteiro E, Reis Lorenzato L, Kenji Nihei O, Junqueira M, Rabinovich GA, et al. (2007) Altered expression of galectin-3 induces cortical thymocyte depletion and premature exit of immature thymocytes during Trypanosoma cruzi infection. Am J Pathol 170: 546-556.
71. Fukumori T, Oka N, Takenaka Y, Nangia-Makker P, Elsamman E, et al. (2006) Galectin-3 regulates mitochondrial stability and antiapoptotic function in response to anticancer drug in prostate cancer. Cancer Res 66: 3114-3119.
72. Matarrese P, Tinari N, Semeraro ML, Natoli C, Iacobelli S, et al. (2000) Galectin-3 overexpression protects from cell damage and death by influencing mitochondrial homeostasis. FEBS Lett 473: 311-315.
73. Yu F, Finley RL Jr, Raz A, Kim HR (2002) Galectin-3 translocates to the perinuclear membranes and inhibits cytochrome c release from the mitochondria. A role for synexin in galectin-3 translocation. J Biol Chem 277: 15819- 15827.
74. de Souza GA, Godoy LM, Teixeira VR, Otake AH, Sabino A, et al. (2006) Proteomic and SAGE profiling of murine melanoma progression indicates the reduction of proteins responsible for ROS degradation. Proteomics 6: 1460- 1470.
75. Kim DW, Kim KH, Yoo BC, Hong SH, Lim YC, et al. (2008) Identification of mitochondrial F(1)F(0)-ATP synthase interacting with galectin-3 in colon cancer cells. Cancer Sci 99: 1884-1891.
76. Carvalho RS, Fernandes VC, Nepomuceno TC, Rodrigues DC, Woods NT, et al. (2014) Characterization of LGALS3 (galectin-3) as a player in DNA damage response. Cancer Biol Ther 15: 840-850.
77. Song S, Ji B, Ramachandran V, Wang H, Hafley M, et al. (2012) Overexpressed galectin-3 in pancreatic cancer induces cell proliferation and invasion by binding Ras and activating Ras signaling. Plos One 7: E42699.
78. Ellerhorst JA, Stephens LC, Nguyen T, Xu XC (2002) Effects of galectin-3 expression on growth and tumorigenicity of the prostate cancer cell line LNCaP. Prostate 50: 64-70.
79. Dumont P, Berton A, Nagy N, Sandras F, Tinton S, et al. (2008) Expression of galectin-3 in the tumor immune response in colon cancer. Lab Invest 88: 896- 906.
80. Machado CM, Andrade LN, Teixeira VR, Costa FF, Melo CM, et al. (2014) Galectin-3 disruption impaired tumoral angiogenesis by reducing VEGF secretion from TGFbeta1-induced macrophages. Cancer Med 3: 201-214.
81. Kim SJ, Shin JY, Lee KD, Bae YK, Choi IJ, et al. (2011) Galectin-3 facilitates cell motility in gastric cancer by up-regulating protease-activated receptor-1 (PAR-1) and matrix metalloproteinase-1 (MMP-1). PLoS One 6: E25103.
82. Kobayashi T, Shimura T, Yajima T, Kubo N, Araki K, et al. (2011) Transient gene silencing of galectin-3 suppresses pancreatic cancer cell migration and invasion through degradation of beta-catenin. Int J Cancer 129: 2775-2786.